Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy.

aPD-L1 NV-based photoimmunotherapy significantly improves the efficacy of photothermal ablation and synergistically enhances subsequent immune activation. This study describes a promising strategy for developing ligand-targeted and personalized cancer photoimmunotherapy.